Stephens Reiterates Overweight Rating for Immunome (NASDAQ:IMNM)

Immunome (NASDAQ:IMNM)‘s stock had its “overweight” rating restated by stock analysts at Stephens in a report issued on Thursday,Benzinga reports. They currently have a $30.00 price target on the stock. Stephens’ target price suggests a potential upside of 266.75% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Lifesci Capital initiated coverage on shares of Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Guggenheim dropped their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Monday, March 10th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.50.

Immunome Stock Down 5.5 %

Shares of IMNM opened at $8.18 on Thursday. The firm has a market cap of $652.58 million, a PE ratio of -1.01 and a beta of 1.93. The company’s fifty day moving average is $9.76 and its two-hundred day moving average is $11.57. Immunome has a fifty-two week low of $8.17 and a fifty-two week high of $26.70.

Immunome (NASDAQ:IMNM) last posted its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, equities research analysts anticipate that Immunome will post -2.21 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Clay B. Siegall bought 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 8.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immunome

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in shares of Immunome in the 4th quarter worth about $70,000. KLP Kapitalforvaltning AS bought a new stake in shares of Immunome in the 4th quarter worth about $75,000. AlphaQuest LLC increased its position in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome in the 4th quarter worth about $95,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.